IL126022A - Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in the preparation of pharmaceutical composition for treating depressive disorders and bipolar disorders - Google Patents

Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in the preparation of pharmaceutical composition for treating depressive disorders and bipolar disorders

Info

Publication number
IL126022A
IL126022A IL12602297A IL12602297A IL126022A IL 126022 A IL126022 A IL 126022A IL 12602297 A IL12602297 A IL 12602297A IL 12602297 A IL12602297 A IL 12602297A IL 126022 A IL126022 A IL 126022A
Authority
IL
Israel
Prior art keywords
disorders
piperidinemethanol
dimethoxyphenyl
fluorophenyl
alpha
Prior art date
Application number
IL12602297A
Other languages
English (en)
Other versions
IL126022A0 (en
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL126022A0 publication Critical patent/IL126022A0/xx
Publication of IL126022A publication Critical patent/IL126022A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12602297A 1996-03-21 1997-02-21 Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in the preparation of pharmaceutical composition for treating depressive disorders and bipolar disorders IL126022A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96400591A EP0796619A1 (de) 1996-03-21 1996-03-21 Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
PCT/US1997/002597 WO1997034603A1 (en) 1996-03-21 1997-02-21 USE OF (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL IN TREATING DEPRESSIVE DISORDERS AND BIPOLAR DISORDERS

Publications (2)

Publication Number Publication Date
IL126022A0 IL126022A0 (en) 1999-05-09
IL126022A true IL126022A (en) 2003-11-23

Family

ID=8225234

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12602297A IL126022A (en) 1996-03-21 1997-02-21 Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in the preparation of pharmaceutical composition for treating depressive disorders and bipolar disorders

Country Status (22)

Country Link
US (2) US6022877A (de)
EP (2) EP0796619A1 (de)
JP (1) JP4165906B2 (de)
KR (1) KR100423018B1 (de)
CN (1) CN1114406C (de)
AR (1) AR006281A1 (de)
AT (1) ATE219672T1 (de)
AU (1) AU704435B2 (de)
BR (1) BR9708109A (de)
CA (1) CA2250077C (de)
DE (1) DE69713571T2 (de)
DK (1) DK0888114T3 (de)
ES (1) ES2175356T3 (de)
HU (1) HU226675B1 (de)
IL (1) IL126022A (de)
NO (2) NO316788B1 (de)
NZ (1) NZ331448A (de)
PT (1) PT888114E (de)
SI (1) SI0888114T1 (de)
TW (1) TW517048B (de)
WO (1) WO1997034603A1 (de)
ZA (1) ZA972345B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796619A1 (de) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
TWI249526B (en) * 1998-03-13 2006-02-21 Aventis Pharma Inc Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
EA003791B1 (ru) * 1998-08-28 2003-10-30 Авентис Фармасьютикалз Инк. Способ лечения больного с расстройством сна
US6939879B2 (en) 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US20020099076A1 (en) 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
US20020161026A1 (en) * 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
KR20030070150A (ko) * 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체
US8501778B2 (en) 2008-06-20 2013-08-06 Nhwa Pharma. Corporation Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021428A (en) * 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US4912117A (en) * 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US4762842A (en) * 1985-10-01 1988-08-09 Eli Lilly And Company Selective method for blocking 5HT2 receptors
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
JPH02138214A (ja) * 1987-12-10 1990-05-28 Merrell Dow Pharmaceut Inc 不安を治療する方法
ATE102482T1 (de) * 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
US5064838A (en) * 1988-01-21 1991-11-12 Merrell Dow Pharmaceuticals 1,4-disubstituted-piperidinyl compounds as pain relievers
ZA891901B (en) * 1988-03-17 1989-11-29 Merrell Dow Pharma Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
US4902691A (en) * 1988-12-19 1990-02-20 Eli Lilly And Company Heteroalkylamides of (8-β)-1-alkyl-6-(substituted)ergolines useful for blocking 5HT2 receptors
US5106855A (en) * 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
CZ198498A3 (cs) * 1995-12-22 1999-03-17 Eli Lilly And Company Použití 2-methyl-4-(4-methyl)-piperazinyl)-10H-thieno[2,3b][1,5]benzodiazepinu
EP0796619A1 (de) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen

Also Published As

Publication number Publication date
US6380216B1 (en) 2002-04-30
ZA972345B (en) 1997-09-25
TW517048B (en) 2003-01-11
NO20033184L (no) 1998-09-18
NO20033184D0 (no) 2003-07-11
PT888114E (pt) 2002-11-29
KR20000064711A (ko) 2000-11-06
ES2175356T3 (es) 2002-11-16
CA2250077C (en) 2003-10-07
NZ331448A (en) 2000-06-23
BR9708109A (pt) 1999-07-27
HU226675B1 (en) 2009-06-29
HUP9902135A2 (hu) 1999-11-29
NO316788B1 (no) 2004-05-10
AR006281A1 (es) 1999-08-11
JP4165906B2 (ja) 2008-10-15
IL126022A0 (en) 1999-05-09
EP0796619A1 (de) 1997-09-24
SI0888114T1 (en) 2002-10-31
EP0888114B1 (de) 2002-06-26
AU704435B2 (en) 1999-04-22
DE69713571D1 (de) 2002-08-01
DE69713571T2 (de) 2003-02-20
EP0888114A1 (de) 1999-01-07
ATE219672T1 (de) 2002-07-15
US6022877A (en) 2000-02-08
NO984348D0 (no) 1998-09-18
CN1213968A (zh) 1999-04-14
JP2000506887A (ja) 2000-06-06
CA2250077A1 (en) 1997-09-25
DK0888114T3 (da) 2002-10-07
NO984348L (no) 1998-09-18
KR100423018B1 (ko) 2004-05-17
HK1019702A1 (en) 2000-02-25
WO1997034603A1 (en) 1997-09-25
CN1114406C (zh) 2003-07-16
HUP9902135A3 (en) 2001-05-28
AU1963197A (en) 1997-10-10

Similar Documents

Publication Publication Date Title
GR3015087T3 (en) (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol.
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
PL344246A1 (en) Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
HUP9902135A3 (en) Use of (+)-alfa-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)-ethyl]-4-piperidinemethanol for producing pharmaceutical compositions suitable for treatment depressive disorders and bipolar disorders
HUP0103832A3 (en) Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof
IL127304A (en) Indoline derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating anxiety and depression
BG105204A (en) Salts of paroxetine
EE200100219A (et) (+)-alfa-(2,3-dimetoksüfenüül)-1-[2-(4-fluorofenüül)etüül]-4-piperidiinmetanooli estrid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
EP0743068A3 (de) Zusammensetzung zur Hemmung von Knochenverlust welche Vanadylsulfat enthält
BG104914A (en) Paroxetine maleate
IL130831A (en) Imino-aza-anthrayclinone derivatives, process for their preparation and pharmaceutical compositions comprising them for the treatment of amyloidosis
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
HUP0203309A3 (en) Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
AU747073C (en) Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of medicament for the treatment of pain
AU4448497A (en) Novel 6 or 7 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
IL121336A0 (en) Therapeutic substance for use in the treatment of AIDS and in the preparation of pharmaceutical compositions for the treatment of AIDS
IL116680A0 (en) Pharmaceutical composition for the treatment of depression
BR1100532A (pt) (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorfenil)etil]-4-pipe ridinometanol e composição contendo o mesmo
AU2003200032A1 (en) Method of treatment and pharmaceutical composition
GB9608927D0 (en) Method of treatment and pharmaceutical composition
HU9700673D0 (en) Method for preparing pharmaceutical composition having an effect on tumourous growth in ectodermal tissues
HUP9903310A3 (en) Indole derivatives for the treatment of osteoporosis pharmaceutical compositions containing them, process for producing them and their medical use
GB9929597D0 (en) New and improved composition and method for the treatment of drug abuse

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees